66 related articles for article (PubMed ID: 35936648)
1. Cover Feature: Aptamers for SARS-CoV-2: Isolation, Characterization, and Diagnostic and Therapeutic Developments (Anal. Sens. 5/2022).
Amini R; Zhang Z; Li J; Gu J; Brennan JD; Li Y
Anal Sens; 2022 Sep; 2(5):e202200035. PubMed ID: 35936648
[No Abstract] [Full Text] [Related]
2. Aptamers for SARS-CoV-2: Isolation, Characterization, and Diagnostic and Therapeutic Developments.
Amini R; Zhang Z; Li J; Gu J; Brennan JD; Li Y
Anal Sens; 2022 Sep; 2(5):e202200012. PubMed ID: 35574520
[TBL] [Abstract][Full Text] [Related]
3. Aptamers as promising nanotheranostic tools in the COVID-19 pandemic era.
Dzuvor CKO; Tettey EL; Danquah MK
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 May; 14(3):e1785. PubMed ID: 35238490
[TBL] [Abstract][Full Text] [Related]
4. Discovery and Characterization of Spike N-Terminal Domain-Binding Aptamers for Rapid SARS-CoV-2 Detection.
Kacherovsky N; Yang LF; Dang HV; Cheng EL; Cardle II; Walls AC; McCallum M; Sellers DL; DiMaio F; Salipante SJ; Corti D; Veesler D; Pun SH
Angew Chem Int Ed Engl; 2021 Sep; 60(39):21211-21215. PubMed ID: 34328683
[TBL] [Abstract][Full Text] [Related]
5. Aptamers-Diagnostic and Therapeutic Solution in SARS-CoV-2.
Wandtke T; Wędrowska E; Szczur M; Przybylski G; Libura M; Kopiński P
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163338
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity.
McAndrews KM; Dowlatshahi DP; Dai J; Becker LM; Hensel J; Snowden LM; Leveille JM; Brunner MR; Holden KW; Hopkins NS; Harris AM; Kumpati J; Whitt MA; Lee JJ; Ostrosky-Zeichner LL; Papanna R; LeBleu VS; Allison JP; Kalluri R
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32796155
[TBL] [Abstract][Full Text] [Related]
7. Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.
Deschambault Y; Lynch J; Warner B; Tierney K; Huynh D; Vendramelli R; Tailor N; Frost K; Sajesh B; LeBlanc K; Layne C; Lin L; Tamming L; Beniac D; Booth S; Carpenter M; Safronetz D; Li X; Kobasa D; Cao J
J Virol; 2022 May; 96(9):e0038922. PubMed ID: 35412347
[TBL] [Abstract][Full Text] [Related]
8. Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies.
Schuler CF; Gherasim C; O'Shea K; Manthei DM; Chen J; Zettel C; Troost JP; Kennedy AA; Tai AW; Giacherio DA; Valdez R; Baldwin JL; Baker JR
Microbiol Spectr; 2021 Oct; 9(2):e0008721. PubMed ID: 34468184
[TBL] [Abstract][Full Text] [Related]
9. Nucleocapsid Specific Diagnostics for the Detection of Divergent SARS-CoV-2 Variants.
Isaacs A; Amarilla AA; Aguado J; Modhiran N; Albornoz EA; Baradar AA; McMillan CLD; Choo JJY; Idris A; Supramaniam A; McMillan NAJ; Muller DA; Young PR; Woodruff TM; Wolvetang EJ; Chappell KJ; Watterson D
Front Immunol; 2022; 13():926262. PubMed ID: 35757714
[TBL] [Abstract][Full Text] [Related]
10. Evolution of SARS-CoV-2 Envelope, Membrane, Nucleocapsid, and Spike Structural Proteins from the Beginning of the Pandemic to September 2020: A Global and Regional Approach by Epidemiological Week.
Troyano-Hernáez P; Reinosa R; Holguín Á
Viruses; 2021 Feb; 13(2):. PubMed ID: 33557213
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Aptamers Targeting the Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein.
Song Y; Song J; Wei X; Huang M; Sun M; Zhu L; Lin B; Shen H; Zhu Z; Yang C
Anal Chem; 2020 Jul; 92(14):9895-9900. PubMed ID: 32551560
[TBL] [Abstract][Full Text] [Related]
12. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
13. [Detection and evaluation of SARS-CoV-2 nucleic acid contamination in corona virus disease 19 ward surroundings and the surface of medical staff's protective equipment].
Yuan XN; Meng QY; Shen N; Li YX; Liang C; Cui M; Ge QG; Li XG; Tan K; Chen Q; Wang J; Zeng XY
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Oct; 52(5):803-808. PubMed ID: 33047711
[TBL] [Abstract][Full Text] [Related]
14. Biochemical characterization of SARS-CoV-2 nucleocapsid protein.
Zeng W; Liu G; Ma H; Zhao D; Yang Y; Liu M; Mohammed A; Zhao C; Yang Y; Xie J; Ding C; Ma X; Weng J; Gao Y; He H; Jin T
Biochem Biophys Res Commun; 2020 Jun; 527(3):618-623. PubMed ID: 32416961
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 Evolutionary Adaptation toward Host Entry and Recognition of Receptor O-Acetyl Sialylation in Virus-Host Interaction.
Kim CH
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32604730
[TBL] [Abstract][Full Text] [Related]
16. Comparison of a laboratory-developed test targeting the envelope gene with three nucleic acid amplification tests for detection of SARS-CoV-2.
Bulterys PL; Garamani N; Stevens B; Sahoo MK; Huang C; Hogan CA; Zehnder J; Pinsky BA
J Clin Virol; 2020 Aug; 129():104427. PubMed ID: 32535398
[TBL] [Abstract][Full Text] [Related]
17. Antibodies against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in individuals with and without COVID-19 vaccination: A method comparison of two different commercially available serological assays from the same manufacturer.
Mueller T
Clin Chim Acta; 2021 Jul; 518():9-16. PubMed ID: 33741357
[TBL] [Abstract][Full Text] [Related]
18. Equine Anti-SARS-CoV-2 Serum (ECIG) Binds to Mutated RBDs and N Proteins of Variants of Concern and Inhibits the Binding of RBDs to ACE-2 Receptor.
Andrade SA; Batalha-Carvalho JV; Curi R; Wen FH; Covas DT; Chudzinski-Tavassi AM; Moro AM
Front Immunol; 2022; 13():871874. PubMed ID: 35898497
[TBL] [Abstract][Full Text] [Related]
19. Rapid Biosensor of SARS-CoV-2 Using Specific Monoclonal Antibodies Recognizing Conserved Nucleocapsid Protein Epitopes.
Lee JH; Jung Y; Lee SK; Kim J; Lee CS; Kim S; Lee JS; Kim NH; Kim HG
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215848
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 neutralizing camelid heavy-chain-only antibodies as powerful tools for diagnostic and therapeutic applications.
Schlör A; Hirschberg S; Amor GB; Meister TL; Arora P; Pöhlmann S; Hoffmann M; Pfaender S; Eddin OK; Kamhieh-Milz J; Hanack K
Front Immunol; 2022; 13():930975. PubMed ID: 36189209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
